149
A combined therapy based on CAR-T and linsitinib, an investigational drug inhibitor of IGF-1R, inhibits the growth of diffuse midline gliomas, rare tumors typical of the pediatric age, very aggressive, inoperable and today still lacking a effective treatment.
The new approach, developed by researchers from the Bambino Gesù Pediatric Hospital in collaboration with the Istituto Superiore di Sanità, Policlinico Gemelli and the Institute of Cancer Research in London, has been successfully tested on experimental models, tumor cell cultures and laboratory animals. but it could represent a hope of cure for some patients.